Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05590962 · ClinicalTrials.gov registry record · NA
Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 562
- Enrollment target
NCT05590962 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 562 participants.
The verdict
NCT05590962, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 562 participants
- Enrollment target
Study Summary
Patients with advanced cancer suffer from high symptom burden and aggressive end-of-life care. Early specialty palliative care is an evidence-based practice that improves symptom burden, quality of life, and survival in advanced cancer. However, over half of patients with advanced cancer die before receiving palliative care. Clinician-level biases and suboptimal identification of high-risk patients are major barriers to palliative care uptake. In this 2-arm pragmatic clinical trial, the investigators will randomize practices within a large community oncology network to receive an intervention consisting of algorithm-based default palliative care referrals. The investigators will study the impact of such an intervention on palliative care utilization and end-of-life outcomes.
Interventions
- OTHER EHR Nudge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 562 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2023-10-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05590962
The ClinicalTrials.gov registry entry for NCT05590962 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 562 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EHR Nudge is the first listed.
NCT05590962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05590962 about?
NCT05590962 is a clinical study titled "Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer". Patients with advanced cancer suffer from high symptom burden and aggressive end-of-life care. Early specialty palliative care is an evidence-based practice that improves symptom burden, quality of life, and survival in advanced cancer. However, over half of patients with advanced cancer die before ...
What is the current status of trial NCT05590962?
This trial is currently completed. It is a NA study. The enrollment target is 562 participants. The study started on 2022-11-09. Estimated completion is 2023-10-03.
What interventions are being tested in trial NCT05590962?
The interventions under investigation include: EHR Nudge (OTHER).
Who is sponsoring clinical trial NCT05590962?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.